Chemo after surgery for triple-negative breast cancer with leftover tumor
Treatments studied
Part of Cancer, Skin clinical trials.
This Phase 2 study tests chemotherapy given after surgery for people with triple-negative breast cancer who still have cancer left after initial (neoadjuvant) chemo. It may help lower the chance the cancer comes back in people at higher risk based on leftover tumor and lymph node findings.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have confirmed invasive breast cancer found on biopsy (not just non-invasive disease).
- Your tumor is “triple negative”: hormone receptors are very low and HER2 is not amplified.
- Your cancer stage is not spread to distant organs (it’s at stages T1–T4, N0–N3, M0).
- You already had at least 4 cycles of chemotherapy before surgery that included both platinum and taxanes, and the cancer did not grow during that time.
- After neoadjuvant chemo, surgery removed the breast tumor and lymph nodes, but you still have leftover invasive cancer (at least 1 cm in the breast and/or positive underarm lymph nodes).
- Your health is strong enough for chemo: you can do daily activities well (ECOG 0–1) and your heart/lungs/liver/kidneys and blood counts are adequate, and surgery to study randomization is within 6 weeks.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of chemotherapy and immunotherapy that avoids a class of drugs called anthracyclines, which can be hard on the heart. The goal is to shrink tumors before surgery for people with triple-negative or low-hormone-receptor breast cancer.
This trial compares two different chemotherapy combinations given before surgery (neoadjuvant therapy) for people with triple-negative breast cancer. It looks to see which drug combination works better to control the cancer before and around the time of the operation.
This trial tests whether a combination of chemotherapy drugs (nab-paclitaxel and carboplatin) plus an immunotherapy drug (PD1 inhibitor) given before surgery can help treat early-stage triple-negative breast cancer. It aims to improve outcomes by using these treatments before the main surgery.
This trial tests a new combination of drugs given before surgery for triple-negative breast cancer. The goal is to see if it can shrink tumors and improve outcomes.
This trial tests a combination of an immunotherapy drug (pembrolizumab) plus two chemotherapy drugs (carboplatin and paclitaxel) given before surgery for people with early-stage, triple-negative breast cancer. The goal is to see if this treatment helps shrink or eliminate the tumor before it's removed.
This trial tests whether adding an immunotherapy drug (HLX10) to chemotherapy before surgery, and then continuing it after surgery, helps people with triple-negative breast cancer more than chemotherapy alone. It is a type of breast cancer that does not respond to hormone treatments or HER2-targeted treatments.
Hear when a new Triple Negative Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.